Phase 4Status unknown
Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis Population
Immunogenicity and Safety of Inactivated COVID-19 Vaccine Coadministered With 23-valent Pneumococcal Polysaccharide Vaccine and Quadrivalent Influenza Vaccine in Hemodialysis Population: a Multicentre, Randomised, Controlled, Phase 4 Trial
- Sponsor
- China National Biotec Group Company Limited (Industry)
- Enrollment
- 1,200 planned
- Conditions
- Hemolysis; COVID-19
- Interventions
- coadministration; COVID-19 vaccine; IIV4+PPV23
- Ages
- adults, older adults
- Registry
- NCT05480436
Full record on ClinicalTrials.gov
From the registry
Evaluation of immunogenicity and safety of inactivated COVID-19 vaccine (BBIBP-Corv) coadministered with PPV23 and IIV4 in hemodialysis population.
Primary outcomes
- Seroconversion rate against SARS-CoV-2
- Seroconversion rate against IIV4
- Seroconversion rate against PPV23
- Neutralizing antibody GMT against SARS-CoV-2
History
Study completion
Primary completion
Last registry update
Started
Registered